Litcius/Paper detail

Luteolin enhances drug chemosensitivity by downregulating the FAK/PI3K/AKT pathway in paclitaxel‑resistant esophageal squamous cell carcinoma

Zhenzhen Yang, Hongtao Liu, Yinsen Song, Na Gao, Pan Gao, Yiran Hui, Yueheng Li, Tianli Fan

2024International Journal of Molecular Medicine21 citationsDOIOpen Access PDF

Abstract

. Luteolin enhanced drug chemosensitivity by downregulating the FAK/PI3K/AKT pathway in PTX‑resistant ESCC and could be a promising agent for the treatment of PTX‑resistant ESCC cancers.

Topics & Concepts

PaclitaxelOncogeneCancer researchEsophageal squamous cell carcinomaPI3K/AKT/mTOR pathwayCell cycleApoptosisMolecular medicineOncologyCellMedicineProtein kinase BBasal cellCell growthChemotherapyInternal medicineCarcinomaBiologyCancerBiochemistryGeneticsCancer, Lipids, and MetabolismLung Cancer Treatments and MutationsEsophageal Cancer Research and Treatment
Luteolin enhances drug chemosensitivity by downregulating the FAK/PI3K/AKT pathway in paclitaxel‑resistant esophageal squamous cell carcinoma | Litcius